Premium
Three patients with advanced cutaneous angiosarcoma treated with eribulin: investigation of serum soluble CD 163 and chemokine (C‐X‐C motif) ligand 10 as possible biomarkers predicting the biological behaviour of angiosarcoma
Author(s) -
Fujimura T.,
Sato Y.,
Kambayashi Y.,
Tanita K.,
Tsukada A.,
Terui H.,
Hashimoto A.,
Aiba S.
Publication year - 2018
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.16676
Subject(s) - angiosarcoma , eribulin , medicine , chemokine , cancer research , dermatology , pathology , receptor , cancer , metastatic breast cancer , breast cancer
Summary Cutaneous angiosarcoma ( CAS ) is a highly aggressive vascular tumour that recurs locally and metastasizes early. Although chemoradiotherapy with taxanes shows a high response rate with prolonged survival, second‐line therapy for advanced CAS remains contentious. This report describes three patients with advanced CAS treated with eribulin. In addition, we investigated serum soluble (s) CD 163, chemokine (C‐X‐C motif) ligand 10 ( CXCL 10) and chemokine (C‐C motif) ligand 2 levels at several time points of tumour progression in these patients, revealing serum levels of sCD 163 and CXCL 10 as potential biomarkers for progression of CAS .